Five‐Year Longitudinal Changes in Treatment Strategies and Clinical Outcomes in Adults With Haemophilia: The ADVANCE Japan Cohort Study

BACKGROUND: Prophylactic treatment for haemophilia has evolved with the introduction of extended half-life (EHL) and nonfactor products. However, long-term real-world data describing how these advances have affected adults with haemophilia remain limited. OBJECTIVES: To evaluate 5-year changes in treatment strategies and clinical outcomes in adults aged ≥40 years with haemophilia. METHODS: We analyzed 5-year longitudinal data from ADVANCE Japan, a nationwide prospective registry of adults aged ≥40 years with haemophilia. RESULTS: Of approximately 600 registered participants, 568 inhibitor-negative individuals were included in this analysis. The median follow-up duration was 4.99 years (Q1-Q3, 4.89-5.92). In haemophilia A, treatment strategies shifted towards EHL and nonfactor therapies over time. Among participants with severe haemophilia A receiving prophylaxis, median injection frequency decreased from 2.0 to 1.0 injection per week over 5 years (p < 0.001). In contrast, among participants with severe haemophilia B, injection frequency remained unchanged (p = 0.563). Despite these therapeutic transitions, annualized bleeding rate (ABR) and annualized joint bleeding rate (AjBR) showed no significant longitudinal changes across age groups in either haemophilia A or B. The proportion of participants with at least one target joint decreased from 88/568 (15.5%) at baseline to 72/548 (13.1%) in 2024. CONCLUSIONS: Over 5 years, treatment strategies in adults with haemophilia A shifted towards EHL and nonfactor therapies, with reduced injection frequency among severe haemophilia A receiving prophylaxis. Bleeding rates remained stable and target joints modestly decreased, suggesting that bleeding outcomes alone may not fully reflect the evolving clinical burden in aging adults with haemophilia. TRIAL REGISTRATION: This study is registered in the Japan Registry of Clinical Trials (JRCT; https://jrct.mhlw.go.jp/latest-detail/jRCT1030190046).

Authors

Institutions

Publication Details

Journal
Haemophilia
Published
2026-08-26
DOI
https://doi.org/10.1111/hae.70370
Primary Topic
Hemophilia Treatment and Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Five‐Year Longitudinal Changes in Treatment Strategies and Clinical Outcomes in Adults With Haemophilia: The ADVANCE Japan Cohort Study

Takeshi Kanematsu, Teruhisa Fujii, Yukio Hiroi, Azusa Nagao et al.
Haemophilia
Hemophilia Treatment and Research
article

Five‐Year Longitudinal Changes in Treatment Strategies and Clinical Outcomes in Adults With Haemophilia: The ADVANCE Japan Cohort Study

Takeshi Kanematsu, Teruhisa Fujii, Yukio Hiroi, Azusa Nagao, Tadashi Matsushita, Kagehiro Amano, Hideyuki Takedani, Masanori Nojima, Naoya Yamasaki, Nobuaki Suzuki, Satoshi Higasa, Akihiro Sawada, Yushi Chikasawa
article en

Abstract

BACKGROUND: Prophylactic treatment for haemophilia has evolved with the introduction of extended half-life (EHL) and nonfactor products. However, long-term real-world data describing how these advances have affected adults with haemophilia remain limited. OBJECTIVES: To evaluate 5-year changes in treatment strategies and clinical outcomes in adults aged ≥40 years with haemophilia. METHODS: We analyzed 5-year longitudinal data from ADVANCE Japan, a nationwide prospective registry of adults aged ≥40 years with haemophilia. RESULTS: Of approximately 600 registered participants, 568 inhibitor-negative individuals were included in this analysis. The median follow-up duration was 4.99 years (Q1-Q3, 4.89-5.92). In haemophilia A, treatment strategies shifted towards EHL and nonfactor therapies over time. Among participants with severe haemophilia A receiving prophylaxis, median injection frequency decreased from 2.0 to 1.0 injection per week over 5 years (p < 0.001). In contrast, among participants with severe haemophilia B, injection frequency remained unchanged (p = 0.563). Despite these therapeutic transitions, annualized bleeding rate (ABR) and annualized joint bleeding rate (AjBR) showed no significant longitudinal changes across age groups in either haemophilia A or B. The proportion of participants with at least one target joint decreased from 88/568 (15.5%) at baseline to 72/548 (13.1%) in 2024. CONCLUSIONS: Over 5 years, treatment strategies in adults with haemophilia A shifted towards EHL and nonfactor therapies, with reduced injection frequency among severe haemophilia A receiving prophylaxis. Bleeding rates remained stable and target joints modestly decreased, suggesting that bleeding outcomes alone may not fully reflect the evolving clinical burden in aging adults with haemophilia. TRIAL REGISTRATION: This study is registered in the Japan Registry of Clinical Trials (JRCT; https://jrct.mhlw.go.jp/latest-detail/jRCT1030190046).

Haemophilia
Kansai Medical University (JP), Tokyo Medical University (JP), Nagoya University Hospital (JP), National Center for Global Health and Medicine (JP), Municipal Tsuruga Hospital (JP), Tokyo Medical University Hospital (JP), University of Tokyo Hospital (JP), Hiroshima University Hospital (JP), Hyogo University (JP)
Jichi Medical University, Hokkaido University, Bayer Yakuhin
Openalex Percentile: Top 10%
Hemophilia Treatment and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.